was able to inhibit the proliferation and induce apoptosis by targeting the ratio of Bcl-2/Bax via inhibiting the antiapoptotic Bcl-2 protein and promoting proapoptotic Bax protein as well as other cellular signaling pathways in breast cancer MCF-7 and MDA-MB-231, gastric cancer GC, ovary cancer SKOV3, fibrosarcoma HT1080, and melanoma A875 cells (Zhang et al., 2010; Yan et al., 2013; Zhang F. et al., 2013; Cui et al., 2015; Xu Z. et al., 2017). This evidence concerns the gene BCL2 and breast cancer.